Literature DB >> 11981146

Neutrophil adhesion molecule expression and serum concentration of soluble adhesion molecules during and after pediatric cardiovascular surgery with or without cardiopulmonary bypass.

Jörg Hambsch1, Pavel Osmancik, József Bocsi, Peter Schneider, Attila Tárnok.   

Abstract

BACKGROUND: Increased neutrophil activation by cardiopulmonary bypass (CPB) during cardiovascular surgery is thought to be responsible for postoperative complications. In children, the contribution of cardiovascular surgery alone to this response is not well-characterized.
METHODS: Children undergoing surgery with CPB (CPB group, n = 35) and without CPB (control, n = 22) were studied (age, 3-17 yr). Blood was drawn 24 h preoperatively before medication, after anesthesia, after connection to CPB, at reperfusion, 4 h to 2 days after surgery, at discharge, and months after surgery. Neutrophil antigen expression and serum concentration of adhesion molecules, interleukin 8, and C5a (fragment of C5 complement) were analyzed by flow cytometry and enzyme-linked immunosorbent assay, respectively.
RESULTS: With and without CPB, anesthesia and surgery induced decreased LFA-1 (CD11a-CD18), Mac-1 (CD11b-CD18), CD45, and CD54 (intercellular adhesion molecule 1) surface expression and sICAM-1 serum concentrations (all P < 0.001). sL-selectin serum concentration decreased with CPB (P < 0.001) but was not significantly altered in the control. In contrast, CD62L expression increased during CPB (P < 0.001). The time course of all analyzed markers was not significantly different between CPB and control, with the exception of sL-selectin (P = 0.017). One-day preoperative baseline values were reached days to months after surgery. Interleukin 8 and C5a serum concentrations increased after surgery in both the CPB group and the control group.
CONCLUSIONS: Pediatric cardiovascular surgery leads to reduced adhesiveness and activity of circulating neutrophils. This reduction is more pronounced and sustained with CPB. These data may be useful in the assessment of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981146     DOI: 10.1097/00000542-200205000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 2.  Hsp70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects.

Authors:  Petrus R de Jong; Alvin W L Schadenberg; Nicolaas J G Jansen; Berent J Prakken
Journal:  Cell Stress Chaperones       Date:  2008-07-31       Impact factor: 3.667

3.  Cardiopulmonary bypass during cardiac surgery modulates systemic inflammation by affecting different steps of the leukocyte recruitment cascade.

Authors:  Jan Rossaint; Christian Berger; Hugo Van Aken; Hans H Scheld; Peter K Zahn; Andreas Rukosujew; Alexander Zarbock
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

4.  Ultrafiltration attenuates cardiopulmonary bypass-induced acute lung injury in a canine model of single-lung transplantation.

Authors:  Masayuki Saitoh; Masanori Tsuchida; Terumoto Koike; Koichi Satoh; Manabu Haga; Tadashi Aoki; Shin-ichi Toyabe; Jun-ichi Hayashi
Journal:  J Thorac Cardiovasc Surg       Date:  2006-12       Impact factor: 5.209

5.  CD62L (L-selectin) shedding for assessment of perioperative immune sensitivity in patients undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Gabor Erdoes; Maria L Balmer; Emma Slack; Istvan Kocsis; Lutz E Lehmann; Balthasar Eberle; Frank Stüber; Malte Book
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

6.  Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection?

Authors:  Dominik Lenz; Jörg Hambsch; Peter Schneider; Hans-Jürgen Häusler; Ursula Sauer; John Hess; Attila Tárnok
Journal:  Crit Care       Date:  2003-03-03       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.